SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

600196

CNE000000X38

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-05-13 pm EDT			5-day change	1st Jan Change
23.97 ^CNY	0.00%		-0.91%	-4.23%

07:15am	Fosun Pharma Unit Fosun Health to Receive Capital Injection from Foshan Chanxi City Investment	MT
06:18am	China Approves Clinical Trials For Breast Cancer Drugs	MT

Shanghai Fosun Pharmaceutical Co., Ltd. Announces Board Appointments

June 25, 2019 at 10:58 am EDT

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. announced that the AGM held on June 25, 2019, elected Mr. Liang Jianfeng as Non-Executive Director. The company also appointed Ms. Li Ling and Mr. Tang Guliang as Independent Non-Executive Director.

Latest news about Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Fosun Pharma Unit Fosun Health to Receive Capital Injection from Foshan Chanxi City Investment	01:15am	MT
China Approves Clinical Trials For Breast Cancer Drugs	12:18am	MT
Fosun Pharma Unit Gets China Marketing Approval for Schizophrenia Tablets	May. 09	MT
Shanghai Fosun Pharmaceutical Unit Secures China Nod to Sell Schizophrenia Drug	May. 09	MT
US FDA Grants Clinical Trial Approval for Fosun Unit's Gastric Cancer Tablets	May. 07	MT
Fosun Pharma's Q1 Profit Slumps 38%	Apr. 30	MT
Shanghai Fosun Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 29	CI
Fosun Pharma Unit Gets Marketing Registration Approval for Tuberculosis Drug from Chinese Regulator	Apr. 24	MT
China Approves Fosun Unit's Phase 2 Clinical Trial for Cancer Combination Therapy	Apr. 18	MT
Fosun Pharma Unit’s New Drug Application for CMV, HSV Drug Accepted by Chinese Regulator	Apr. 17	MT
China Accepts New Drug Applications for Fosun Pharma's Iron Overload Syndrome Drugs	Apr. 08	MT
Tranche Update on Shanghai Fosun Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on March 27, 2024.	Apr. 02	CI
Telefield Medical Imaging Limited announced that it has received HKD 59.571525 million in funding Gobi Partners	Mar. 30	CI
Fosun Pharma's 2023 Attributable Profit Declines, Misses Estimates	Mar. 26	MT
Shanghai Fosun Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 200 million worth of its shares.	Mar. 26	CI
Shanghai Fosun Pharmaceutical Co., Ltd. Proposes Final Dividend for the Year Ended 31 December 2023	Mar. 26	CI
Shanghai Fosun Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
Shanghai Fosun Pharmaceutical Co., Ltd. authorizes a Buyback Plan.	Mar. 25	CI
Shanghai Fosun Pharma Unit's Oral Schizophrenia Drug Gets Marketing Registration	Mar. 14	MT
Fosun Pharma Unit Gets China OK for Phase I Trial for Solid Tumor Drug	Mar. 08	MT
Fosun Pharma Unit to Start First Phase of Trial of Cancer Drug Candidate	Mar. 07	MT
Fosun Pharma Chairman Proposes Buyback of Up to 200 Million Yuan	Mar. 04	MT
Fosun Pharma Subsidiaries Get Nod to Trial Leukemia Drugs	Feb. 29	MT
Registration Application of Hypokalemia Drug by Shanghai Fosun Pharmaceutical Unit Accepted by Chinese Regulator	Feb. 20	MT
Yuyuan Tourist Mart CFO Steps Down	Feb. 05	MT

Chart Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Duration

Period

Chart Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

More charts

Company Profile

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a pharmaceutical group organized around 4 areas of activities: - research, development and manufacturing of medicines (72.1% of net sales): for the treatment of cardiovascular diseases, digestive tract, metabolism, central nervous system and blood system disorders, and infectious diseases; - sale of medical equipments and diagnosis products (17.3%); - medical and hospital services (10.5%); - other (0.1%). China accounts for 72.9% of net sales.

Sector

Pharmaceuticals

Calendar

2024-08-25 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

23.97 CNY

Average target price

28.61 CNY

Spread / Average Target

+19.34%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.	-4.23%	7.97B
ELI LILLY AND COMPANY	+31.06%	688B
NOVO NORDISK A/S	+30.35%	588B
JOHNSON & JOHNSON	-3.42%	364B
MERCK & CO., INC.	+18.02%	326B
ABBVIE INC.	+4.27%	285B
ASTRAZENECA PLC	+15.53%	239B
NOVARTIS AG	+10.16%	210B
ROCHE HOLDING AG	-8.14%	200B
AMGEN INC.	+8.12%	167B

Other Pharmaceuticals

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Equities

600196

CNE000000X38

Pharmaceuticals

Shanghai Fosun Pharmaceutical Co., Ltd. Announces Board Appointments

EPS Revisions